Challenger Stock Forecast, Price & News

Wall Street analysts have given Challenger a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Challenger wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Challenger is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Challenger.

Challenger Limited (ASX:CGF) released its quarterly earnings data on Tuesday, August, 13th. The company reported $0.61 EPS for the quarter, missing the consensus estimate of $0.61 by $0.00.
View Challenger's earnings history.

Challenger announced a Interim dividend on Wednesday, February 10th. Stockholders of record on Tuesday, March 23rd will be given a dividend of 0.095 per share on Tuesday, March 23rd. This represents a dividend yield of 1.48%. The ex-dividend date of this dividend is Tuesday, February 23rd.
View Challenger's dividend history.

Challenger pays an annual dividend of A$0.19 per share and currently has a dividend yield of 3.26%.
View Challenger's dividend history.

Some companies that are related to Challenger include (BTT.AX) (BTT), (CDI.L) (CDI), (DP3D.L) (DP3D), (TBGR.L) (TBGR), (TRE.L) (TRE), (WDE.AX) (WDE), 360 Capital Digital Infrastructure Fund (GDC), 360 Capital Digital Infrastructure Fund (TDI), 360 Capital Enhanced Income Fund (TCF), 3i Group (TGOPF), 3i Group (TGOPY), 8IP Emerging Companies (8EC), Aberdeen Australia Equity Fund (IAF), Aberdeen Emerging Markets Equity Income Fund (AEF) and Aberdeen Global Premier Properties Fund (AWP).
View all of CGF's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Challenger investors own include Abbott Laboratories (ABT), BHP Group (BHP), Isentia Group (ISD), South32 (S32), AbbVie (ABBV), Goldman Sachs Physical Gold ETF (AAAU), Argo Investments (ARG), Arcturus Therapeutics (ARCT), Appen (APX) and Afterpay (APT).

Challenger trades on the ASX under the ticker symbol "CGF."

Challenger has a market capitalization of $0.00 and generates $1.88 billion in revenue each year.

Challenger employs 709 workers across the globe.

The official website for Challenger is www.challenger.com.au.

Challenger is headquartered at L 2 5 Martin Pl, SYDNEY, NSW 2000, Australia.

Challenger's mailing address is L 2 5 Martin Pl, SYDNEY, NSW 2000, Australia. The company can be reached via phone at +61-2-99947000.